Prednisolone
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PEDIAPRED | — | 1998-12-17 | fda.gov ↗ |
| Label expansion | US (FDA) | OMNIPRED | — | 1995-08-29 | fda.gov ↗ |
| Approved | US (FDA) | METICORTELONE | — | 1955-05-22 | fda.gov ↗ |
Trials 272 · started per year
Also used as a comparator or background therapy in 513 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05620901 Comparator | Feb 2023 → Feb 2025 | Coats disease, exudative vitreoretinopathy, retinal lattice degeneration, retinal perforation +1 | Lejla Vajzovic, MD, FASRS | Completed | No outcome recorded |
| Phase 0 | NCT03491098 Comparator | May 2018 → Apr 2019 | otitis media with effusion | Muteea Mubark Salmen Bakuwiri | Unknown | No outcome recorded |
| Phase 0 | NCT03087968 Background | Jul 2016 → Sep 2017 | alcoholic hepatitis | HepQuant, LLC | Withdrawn | No outcome recorded |
| Phase 125 trials | ||||||
| Phase 1 | NCT07572071 Background | Aug 2025 → Aug 2028 expected | Parkinson disease | Royan Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT06483802 Background | Nov 2024 → Oct 2025 | Friedreich ataxia, cardiomyopathy | Astellas Gene Therapies | Withdrawn | No outcome recorded |
| Phase 1 | NCT06421935 Background | Aug 2024 → Feb 2027 expected | neoplasm | EMD Serono Research & Development Institute, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05295927 Background | Mar → Sep 2022 | prostate neoplasm | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT06193993 Background | Nov 2021 → Sep 2023 overdue | castration-resistant prostate carcinoma, metastatic malignant neoplasm | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07380152 Comparator | Aug 2021 → Jun 2022 | post-COVID-19 disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 1 | NCT05003089 Comparator | Jun → Dec 2021 | immune dysregulation, autoimmunity, and autoinflammation | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04071262 Background | Dec 2019 → Feb 2021 | cancer of unknown primary site | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03792256 Background | Apr 2019 → Jun 2021 | T lymphoblastic leukemia/lymphoma, T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT03777319 Comparator | Dec 2018 → Sep 2021 | Duchenne muscular dystrophy | Kevin Flanigan | Terminated | No outcome recorded |
| Phase 1 | NCT03585556 Background | Sep 2018 → Jan 2020 | wet macular degeneration | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03497273 Background | Mar 2018 → Nov 2019 | acute graft versus host disease | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02872597 Background | Sep 2016 → Aug 2018 | status asthmaticus | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02760316 Comparator | May 2016 → Sep 2017 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02625467 Background | Jun 2013 → Jun 2014 | keratoconus | Instituto de Oftalmología Fundación Conde de Valenciana | Completed | No outcome recorded |
| Phase 1 | NCT01370694 Background | Aug 2011 → Dec 2014 | follicular lymphoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT01884428 Background | Jul 2011 → Mar 2014 | Hodgkins lymphoma | Armando Santoro, MD | Unknown | No outcome recorded |
| Phase 1 | NCT01324583 Background | Jan 2011 → Nov 2014 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02217631 Comparator | Oct 2009 → Mar 2010 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00812825 Comparator | Jan → Jul 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00985959 Background | Jul 2008 → Jun 2010 | plasma cell myeloma | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT00849888 Background | Apr 2008 → Feb 2011 | DiGeorge syndrome | Sumitomo Pharma Switzerland GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT00600535 Background | Jul 2007 → Mar 2012 | prostate neoplasm | Cougar Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00562068 Background | May 2007 → May 2009 | lymphoma, small intestine cancer | Cancer Research UK | Unknown | No outcome recorded |
| Phase 1 | NCT01664728 Background | Apr 2007 → Feb 2009 | prostate neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1/232 trials | ||||||
| Phase 1/2 | NCT07387926 Background | Jul 2026 → Sep 2033 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), acute lymphoblastic leukemia | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07052929 Background | Dec 2025 → Oct 2027 expected | X-linked myotubular myopathy | Astellas Gene Therapies | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07270549 Background | Nov 2025 → Dec 2032 expected | CTNNB1-related neurodevelopmental disorder and/or vitreoretinopathy | CTNNB1 Foundation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07035379 Background | Sep 2025 → Sep 2026 expected | diffuse large B-cell lymphoma | Zhejiang Teruisi Pharmaceutical Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06235567 Comparator | Apr 2025 → Aug 2026 overdue | keratoconus | Maanasa Indaram, MD | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT06531018 Background | Feb → Aug 2025 overdue | autoimmune thrombocytopenia | Renata PLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06871007 Background | Sep 2024 → Sep 2029 expected | primary mediastinal large B-cell lymphoma | St. Petersburg State Pavlov Medical University | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT06681688 Comparator | Jul 2024 → Jun 2025 overdue | cataract | Inder Paul Singh, M.D. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06594640 Background | May 2024 → Jun 2026 overdue | diffuse large B-cell lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05821075 Comparator | Aug 2023 → Jan 2026 overdue | Bell's palsy | October 6 University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05320380 Background | Aug → Sep 2023 | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia | Children's Oncology Group | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05230680 Background | Jul 2022 → Dec 2026 expected | T-cell non-Hodgkin lymphoma | Won Seog Kim | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05143502 Background | Jan 2022 → Jan 2024 | chronic rhinosinusitis | Assiut University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04914741 Background | Jun 2021 → Dec 2023 overdue | high grade B-cell lymphoma | Peter MacCallum Cancer Centre, Australia | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04661007 Background | Dec 2020 → Jul 2025 overdue | diffuse large B-cell lymphoma | Incyte Biosciences Japan GK | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04423926 Background | Jun 2020 → Dec 2022 | ALK-negative anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03920007 Background | Sep 2019 → May 2023 overdue | Leber congenital amaurosis 1 | Atsena Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03586999 Background | Nov 2018 → May 2021 | peripheral T-cell lymphoma, not otherwise specified | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1/2 | NCT03793478 Background | Aug 2018 → May 2027 expected | acute myeloid leukemia | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03517085 Background | May 2018 → Nov 2021 | glycogen storage disease I | Ultragenyx Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT02991144 Background | Jul 2017 → Dec 2021 | ornithine carbamoyltransferase deficiency | Ultragenyx Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT03571308 Background | Jun 2017 → Jan 2020 | non-Hodgkin lymphoma | University Hospital Southampton NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1/2 | NCT02889523 Background | Oct 2016 → Jan 2023 overdue | diffuse large B-cell lymphoma, follicular lymphoma | The Lymphoma Academic Research Organisation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02309385 Comparator | Oct 2014 → Mar 2017 | non-infectious anterior uveitis | Aciont Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT01992653 Background | Nov 2013 → Dec 2018 | non-Hodgkin lymphoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01897571 Background | Jun 2013 → Aug 2021 | follicular lymphoma, primary mediastinal large B-cell lymphoma | Epizyme, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01647685 Comparator | May 2012 → May 2013 | atherosclerosis | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| Phase 1/2 | NCT01601106 Comparator | Sep 2011 → May 2013 | atherosclerosis | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| Phase 1/2 | NCT00920933 Comparator | Jan → Nov 2009 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00379574 Background | Sep 2006 → Jan 2011 | diffuse large B-cell lymphoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00473746 Background | Jun 2006 → Dec 2012 | prostate neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT00579527 Background | Dec 2005 → Dec 2011 | DiGeorge syndrome | Sumitomo Pharma Switzerland GmbH | Completed | No outcome recorded |
| Phase 2103 trials | ||||||
| Phase 2 | NCT07710157 Comparator | Jul 2026 → Jun 2028 expected | minimal change disease | Medical University Innsbruck | Recruiting | No outcome recorded |
| Phase 2 | NCT07172659 Comparator | May 2026 → Jan 2027 expected | erythema nodosum | Medicines Development for Global Health | Recruiting | No outcome recorded |
| Phase 2 | NCT07503379 Background | Apr 2026 → Dec 2027 expected | — | Yonghong Li | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06953791 Comparator | Feb 2026 → Feb 2028 expected | Crohn disease | University Hospital Tuebingen | Recruiting | No outcome recorded |
| Phase 2 | NCT07091175 Background | Nov 2025 → Feb 2028 expected | nephrotic syndrome | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 2 | NCT07005154 Background | Jun 2025 → May 2032 expected | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06676579 Comparator | Jun 2025 → Mar 2028 expected | IgA glomerulonephritis | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT06317662 Background | Jun 2025 → Dec 2028 expected | B-cell acute lymphoblastic leukemia, acute leukemia of ambiguous lineage | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT06124157 Background | May 2025 → Dec 2030 expected | B-cell acute lymphoblastic leukemia | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT06819670 Comparator | May 2025 → Feb 2028 expected | infantile spasms | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 2 | NCT06918015 Background | May 2025 → May 2028 expected | follicular lymphoma | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06474442 Background | Apr 2025 → Dec 2026 expected | stromal keratitis | Shanghai BDgene Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06890884 Background | Apr 2025 → Dec 2027 expected | diffuse large B-cell lymphoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT05762640 Background | Nov 2024 → May 2027 expected | hemophagocytic syndrome | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT07553988 Comparator | Oct 2024 → May 2026 overdue | prostate carcinoma | R-Pharm International, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06467526 Background | Jul 2024 → May 2026 overdue | sudden sensorineural hearing loss | Chang Gung Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05761171 Background | Jan 2024 → Dec 2027 expected | acute lymphoblastic leukemia, mixed phenotype acute leukemia | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06679153 Comparator | Nov 2023 → Dec 2024 | anterior uveitis | VivaVision Biotech, Inc | Completed | No outcome recorded |
| Phase 2 | NCT05874778 Background | May 2023 → May 2026 | diffuse large B-cell lymphoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06155604 Background | Jan 2023 → Dec 2026 expected | chronic kidney disease, lupus nephritis | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT05776459 Comparator | Oct 2022 → Feb 2026 overdue | sensorineural hearing loss disorder | AudioCure Pharma GmbH | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05489211 Background | Sep 2022 → Oct 2027 expected | biliary tract cancer, castration-resistant prostate carcinoma, colorectal cancer, endometrial cancer +3 | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT05406401 Background | Jul 2022 → Apr 2029 expected | diffuse large B-cell lymphoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05461261 Background | Jul 2022 → Jun 2025 | DNA repair disease, chemotherapy-induced toxicity, prostate carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 2 | NCT05369039 Comparator | Jun 2022 → Mar 2023 | chronic rhinosinusitis | Menoufia University | Unknown | No outcome recorded |
| Phase 2 | NCT04706741 Background | Jan → Aug 2022 | uveitis | ACELYRIN Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04546620 Background | Oct 2021 → Nov 2027 expected | diffuse large B-cell lymphoma | University Hospital Southampton NHS Foundation Trust | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04797325 Comparator | Aug 2021 → Apr 2025 | — | University of Copenhagen | Unknown | No outcome recorded |
| Phase 2 | NCT04736108 Background | May 2021 → Oct 2022 | prostate cancer | West China Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04701034 Comparator | Jan 2021 → Apr 2024 | habitual spontaneous abortion, pregnancy disorder with abortive outcome, pregnancy loss, recurrent, 4 | Aalborg University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04479267 Background | Aug 2020 → Jun 2025 overdue | high grade B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement | Barbara Ann Karmanos Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04263584 Background | Jun 2020 → Apr 2025 | diffuse large B-cell lymphoma | University Hospital Muenster | Unknown | No outcome recorded |
| Phase 2 | NCT06336395 Background | Mar 2020 → Mar 2030 expected | B-cell acute lymphoblastic leukemia | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 2 | NCT05406999 Background | Feb 2020 → Dec 2026 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT04023916 Background | Dec 2019 → Jul 2020 | diffuse large B-cell lymphoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT03899337 Background | Jul 2019 → Oct 2025 overdue | Richter transformation | University of Birmingham | Recruiting | No outcome recorded |
| Phase 2 | NCT03967925 Comparator | Feb 2019 → Apr 2023 | granulomatosis with polyangiitis | Rachel Jones | Unknown | No outcome recorded |
| Phase 2 | NCT03765788 Background | Jan 2019 → Jun 2021 | temporal arteritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT04181489 Background | Jan 2019 → Dec 2023 | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT03715881 Comparator | Dec 2018 | non-arteritic anterior ischemic optic neuropathy | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT03643107 Background | Oct 2018 → Oct 2021 | castration-resistant prostate carcinoma | Allarity Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03399513 Background | May 2018 → Dec 2023 | diffuse large B-cell lymphoma | University Hospital Muenster | Completed | No outcome recorded |
| Phase 2 | NCT03407144 Background | Apr 2018 → Nov 2026 expected | classic Hodgkin lymphoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03368235 Comparator | Jan 2018 → Nov 2019 | rheumatoid arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT03708718 Comparator | Dec 2017 → Mar 2021 | systemic sclerosis | Prof. Ariane herrick | Completed | No outcome recorded |
| Phase 2 | NCT03320434 Comparator | Oct 2017 → Feb 2018 | conjunctivitis | ORA, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03188068 Comparator | Jun 2017 → Dec 2021 | Kasabach-Merritt syndrome, kaposiform hemangioendothelioma | West China Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03111810 Comparator | May 2017 → Aug 2020 | exogenous Cushing syndrome | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT03286634 Background | Apr 2017 → Mar 2028 expected | Down syndrome, acute lymphoblastic leukemia, childhood malignant neoplasm | National Hospital Organization Nagoya Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02828358 Background | Apr 2017 → Sep 2020 | B-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02776059 Comparator | Jan 2017 → Mar 2020 | alcoholic hepatitis | Timothy Morgan, MD | Completed | No outcome recorded |
| Phase 2 | NCT04114188 Background | Dec 2016 → Dec 2020 | transplant rejection | Prof. Dr. Petra Reinke | Completed | No outcome recorded |
| Phase 2 | NCT03067753 Comparator | Dec 2016 → Sep 2019 | radiation-induced disorder | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02904772 Background | Oct 2016 → Jun 2020 | familial lipoprotein lipase deficiency | UniQure Biopharma B.V. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02854631 Background | Sep 2016 → Feb 2018 | alcoholic hepatitis | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02670616 Background | May 2016 → Jun 2020 | diffuse large B-cell lymphoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02949349 Background | Jul 2015 → Dec 2016 | lupus nephritis | Genovate Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02631603 Comparator | Apr 2015 → Jul 2016 | hypersensitivity pneumonitis | Matthias Griese | Terminated | No outcome recorded |
| Phase 2 | NCT02229136 Comparator | Sep 2014 → Nov 2022 | breast cancer, stomatitis | US Oncology Research | Completed | No outcome recorded |
| Phase 2 | NCT01972217 Comparator | Apr 2014 → Sep 2017 | prostate carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT01679119 Background | Oct 2013 → Mar 2019 | diffuse large B-cell lymphoma | University College, London | Completed | No outcome recorded |
| Phase 2 | NCT01762540 Comparator | Jan 2013 → Jun 2014 | — | University of Aarhus | Completed | No outcome recorded |
| Phase 2 | NCT01615874 Background | Jan → Sep 2013 | asthma | Organon and Co | Withdrawn | No outcome recorded |
| Phase 2 | NCT01673191 Comparator | Nov 2012 → Dec 2014 | diabetes mellitus, macular retinal edema | Retinal Consultants of Arizona | Completed | No outcome recorded |
| Phase 2 | NCT02890602 Background | Sep 2012 → Nov 2017 | diffuse large B-cell lymphoma | Kosin University Gospel Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01756638 Background | Jun 2012 → Oct 2014 | prostate cancer | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01795703 Background | Jun 2012 → Oct 2014 | prostate cancer | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01719835 Comparator | Mar 2012 → Nov 2016 | ALK-negative anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma +1 | Royal Marsden NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 2 | NCT01448213 Comparator | Oct 2011 → Jan 2014 | Fuchs' endothelial dystrophy, bullous keratopathy | Price Vision Group | Completed | No outcome recorded |
| Phase 2 | NCT01450137 Background | Sep 2011 → Dec 2014 | temporal arteritis | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 2 | NCT01685983 Background | Aug 2011 → Jan 2013 | prostate cancer | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01369745 Comparator | Jun 2011 → Aug 2012 | rheumatoid arthritis | Zalicus | Completed | No outcome recorded |
| Phase 2 | NCT01085097 Background | Sep 2010 → Oct 2012 | lupus nephritis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01179490 Background | Sep 2010 → Sep 2011 | plasma cell myeloma | SymBio Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00919776 Comparator | Aug 2010 → Dec 2012 | leprosy | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01173887 Comparator | Jul 2010 → Apr 2012 | adult T-cell leukemia/lymphoma | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00919542 Comparator | Jul 2010 → Dec 2012 | leprosy | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01487902 Comparator | Jul 2010 → Oct 2013 | castration-resistant prostate carcinoma | Asan Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00967226 Comparator | Jul 2009 → Jan 2013 | hemangioma | Nancy Bauman | Terminated | No outcome recorded |
| Phase 2 | NCT01005758 Background | Jan 2009 → Jan 2013 | leukemia | Ohio State University Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 2 | NCT00844298 Background | Jan 2009 → Jun 2012 | leukemia | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00782717 Background | Nov 2008 → Jul 2010 | macular retinal edema | Alcon Research | Completed | No outcome recorded |
| Phase 2 | NCT00751205 Background | Aug 2008 → Feb 2010 | ovarian carcinoma, prostate cancer | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00623766 Background | Jul 2008 → Sep 2009 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00699803 Comparator | May → Aug 2008 | cataract | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 2 | NCT00551707 Comparator | Oct 2007 → Nov 2008 | rheumatoid arthritis | Zalicus | Completed | No outcome recorded |
| Phase 2 | NCT00521989 Comparator | Aug 2007 → Jul 2009 | osteoarthritis, knee | Zalicus | Terminated | No outcome recorded |
| Phase 2 | NCT01299948 Comparator | Jun 2007 → Mar 2011 | HIV infectious disease | Medical Mission Institute, Germany | Completed | No outcome recorded |
| Phase 2 | NCT00494780 Comparator | Jun 2007 → Apr 2009 | follicular lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00723268 Comparator | May 2007 → Aug 2008 | mouth disorder | Mashhad University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT00474383 Background | Nov 2006 → Aug 2011 | prostate neoplasm | Cougar Biotechnology, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00513955 Background | Jun 2006 → Oct 2014 | lymphoma | University Hospital Plymouth NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT00664599 Background | Apr 2006 → Jan 2008 | Behcet disease | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00379990 Comparator | Jan 2006 → Dec 2007 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00498797 Background | Dec 2005 → Jul 2007 | hormone-resistant prostate carcinoma, metastatic prostate carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00618501 Background | Oct 2005 → Dec 2008 | leukemia | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00213252 Comparator | Sep 2005 → Feb 2008 | asthma | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 2 | NCT00723086 Background | May 2005 → Sep 2008 | — | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00554918 Background | Feb 2005 → Dec 2008 | metastatic malignant neoplasm, prostate cancer | University Hospital Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT00079105 Comparator | Jan 2004 → Dec 2010 | lymphoma | Newcastle-upon-Tyne Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT00753103 Background | Jan 2003 → Jul 2006 | granulomatosis with polyangiitis, microscopic polyangiitis | University Hospital Birmingham NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT00130195 Background | Sep 2002 → Feb 2008 | acute lymphoblastic leukemia | Japan Adult Leukemia Study Group | Completed | No outcome recorded |
| Phase 2 | NCT00131053 Background | Sep 2002 → May 2011 | acute lymphoblastic leukemia | Japan Adult Leukemia Study Group | Unknown | No outcome recorded |
| Phase 2/326 trials | ||||||
| Phase 2/3 | NCT07072585 Background | Aug 2026 → Sep 2035 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Children's Oncology Group | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07569081 Background | Aug 2026 → Dec 2028 expected | VEXAS syndrome | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07571681 Comparator | Jul 2026 → Jul 2027 expected | Hashimoto thyroiditis, subacute thyroiditis | Mansoura University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07634471 Background | Jun 2026 → Jul 2032 expected | follicular lymphoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06650124 Comparator | Nov 2024 → Dec 2025 overdue | autoimmune hepatitis | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05694130 Background | Feb 2023 → Sep 2024 | Sjogren syndrome | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05341401 Comparator | Jun 2022 → Jun 2023 | ulcerative colitis | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05284136 Comparator | Apr 2022 → Aug 2025 | Crohn disease | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2/3 | NCT05961202 Background | Nov 2021 → Sep 2024 overdue | myocarditis | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04206553 Background | Oct 2020 → Jul 2024 | bullous pemphigoid | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT04227483 Comparator | Jan 2020 → Jul 2025 overdue | allergic bronchopulmonary aspergillosis | Post Graduate Institute of Medical Education and Research, Chandigarh | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04074187 Background | Oct 2019 → May 2021 | thrombotic thrombocytopenic purpura | Sanofi | Completed | No outcome recorded |
| Phase 2/3 | NCT03418779 Background | Jul 2019 → Sep 2024 overdue | IgA glomerulonephritis | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03876444 Comparator | Apr 2019 → Apr 2022 | infantile spasms | Suvasini Sharma | Unknown | No outcome recorded |
| Phase 2/3 | NCT04652739 Comparator | Oct 2018 → Mar 2019 | oral erosive lichen | Nourhan M.Aly | Completed | No outcome recorded |
| Phase 2/3 | NCT03503227 Comparator | Apr → Oct 2018 | female infertility | Kasr El Aini Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT03133299 Background | Dec 2016 → Jun 2018 | allergic bronchopulmonary aspergillosis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2/3 | NCT02440009 Background | May 2014 → Jul 2017 | allergic bronchopulmonary aspergillosis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 2/3 | NCT01769352 Comparator | Aug 2012 → Apr 2016 | cystoid macular edema | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/3 | NCT00919815 Comparator | Aug 2010 → Dec 2012 | leprosy | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT00836810 Comparator | Oct 2009 → Nov 2010 | polymyalgia rheumatica | University Hospitals Bristol and Weston NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2/3 | NCT01045837 Comparator | Apr 2009 → Apr 2010 | celiac disease | All India Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00795756 Comparator | Jan 2008 → Oct 2013 | acute lymphoblastic leukemia | Northern Italy Leukemia Group | Completed | No outcome recorded |
| Phase 2/3 | NCT00430677 Background | Jun 2007 → Sep 2010 | systemic lupus erythematosus | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2/3 | NCT00268476 Background | Jul 2005 → Mar 2026 overdue | prostate cancer | Medical Research Council | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00468871 Comparator | Apr 2002 → Jun 2006 | uveitis | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 3150 trials | ||||||
| Phase 3 | NCT07075315 Comparator | Jan 2028 → Dec 2031 expected | liver disorder | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07365995 Comparator | Apr 2026 → Feb 2031 expected | prostate carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 3 | NCT06120673 Comparator | Oct 2025 → Jan 2028 | idiopathic membranous glomerulonephritis | The University of Queensland | Withdrawn | No outcome recorded |
| Phase 3 | NCT07136805 Comparator | Oct 2025 → Dec 2026 expected | non-infectious anterior uveitis | VivaVision Biotech, Inc | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06952803 Background | Aug 2025 → Mar 2033 expected | prostate cancer | AstraZeneca | Recruiting | No outcome recorded |
| Show all 150 trials opens the full record — a long page | ||||||
| Phase 4116 trials | ||||||
| Phase 4 | NCT06892197 Comparator | Mar 2026 → Aug 2030 expected | pneumonia | Copenhagen Respiratory Research | Recruiting | No outcome recorded |
| Phase 4 | NCT07341776 Comparator | Jan → Dec 2026 expected | anaphylaxis, food allergy | Johannes Trueck | Recruiting | No outcome recorded |
| Phase 4 | NCT07281807 Comparator | Jan → Dec 2026 expected | periapical periodontitis | RANA AHMAD | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07151456 Comparator | Jan 2026 → Dec 2029 expected | idiopathic nephrotic syndrome | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07227428 Comparator | Dec 2025 → Dec 2027 expected | rheumatoid arthritis | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| Show all 116 trials opens the full record — a long page | ||||||
| Phase not applicable55 trials | ||||||
| — | NCT07498842 Comparator | Mar 2026 → Jun 2027 expected | sarcoidosis | Royal Brompton & Harefield NHS Foundation Trust | Recruiting | No outcome recorded |
| — | NCT07172685 Background | Jul 2025 → Jun 2026 overdue | prostate cancer | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| — | NCT06298383 Comparator | Jun 2025 → Feb 2026 | pulpitis | Cairo University | Completed | No outcome recorded |
| — | NCT06654596 Comparator | Dec 2024 → Dec 2026 expected | IgA glomerulonephritis | Ruijin Hospital | Recruiting | No outcome recorded |
| — | NCT06732622 Background | Dec 2024 → May 2026 overdue | Bell's palsy | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| — | NCT07235488 Comparator | Jul 2024 → May 2026 overdue | sudden hearing loss disorder | China Medical University Hospital | Recruiting | No outcome recorded |
| — | NCT06306612 Background | Mar 2024 → Dec 2028 expected | prostate cancer | RenJi Hospital | Recruiting | No outcome recorded |
| — | NCT06860620 Background | Jan → Dec 2024 | nephrotic syndrome of childhood - steroid sensitive | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT07567118 Comparator | May 2023 → Jan 2025 | cataract | Damascus University | Completed | No outcome recorded |
| — | NCT05781516 Background | Jan 2023 → Jun 2024 | immunoglobulin G4-related sclerosing disease | Wen Zhang | Unknown | No outcome recorded |
| — | NCT03775460 Background | Jan 2023 → Sep 2025 overdue | erythema nodosum | London School of Hygiene and Tropical Medicine | Active not recruiting | No outcome recorded |
| — | NCT05248139 Comparator | Oct 2022 → Feb 2023 | cataract, ocular hypertension | Visualiza | Unknown | No outcome recorded |
| — | NCT04767711 Comparator | May → Dec 2022 | bone resorption disease | Sahlgrenska University Hospital | Completed | No outcome recorded |
| — | NCT05105256 Comparator | Dec 2021 → May 2024 | osteoarthritis | Reims University Hospital | Completed | No outcome recorded |
| — | NCT06280794 Background | Mar 2021 → Jan 2026 | Bell's palsy | Beijing Tongren Hospital | Unknown | No outcome recorded |
| — | NCT04705584 Comparator | Jan → Oct 2021 | vernal keratoconjunctivitis | Assiut University | Unknown | No outcome recorded |
| — | NCT04662125 Comparator | Dec 2020 → Aug 2023 | — | Zagazig University | Completed | No outcome recorded |
| — | NCT04657484 Comparator | Dec 2020 → Sep 2021 | post-COVID-19 disorder | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| — | NCT04590183 Comparator | Oct 2020 → Aug 2021 | glaucomatocyclitic crisis | Peking University | Unknown | No outcome recorded |
| — | NCT04463420 Background | Aug → Nov 2020 | COVID-19 | Baqiyatallah Medical Sciences University | Unknown | No outcome recorded |
| — | NCT04871633 Background | Aug → Nov 2020 | COVID-19 | King Edward Medical University | Completed | No outcome recorded |
| — | NCT03647852 Background | Sep 2019 → Feb 2026 overdue | immunoglobulin A vasculitis | Children's Hospital of Fudan University | Recruiting | No outcome recorded |
| — | NCT03856229 Comparator | Mar 2019 → Aug 2026 overdue | HIV infectious disease, pneumocystosis | Center for Research in Infectious Diseases | Enrolling by invitation | No outcome recorded |
| — | NCT03852355 Comparator | Feb → Sep 2019 | headache disorder, rheumatoid arthritis | Assiut University | Completed | No outcome recorded |
| — | NCT05850143 Comparator | Jan 2019 → Dec 2023 | childhood onset asthma | DR. MOHAMMAD ALI ARIF | Unknown | No outcome recorded |
| — | NCT03601611 Background | Jan 2019 → Jan 2020 | arthritic joint disease, cancer, colitis | Herlev Hospital | Completed | No outcome recorded |
| — | NCT03779360 Comparator | Oct 2018 → Feb 2019 | dermatitis | Centre for Human Drug Research, Netherlands | Completed | No outcome recorded |
| — | NCT04982809 Comparator | Jul 2018 → Mar 2020 | interstitial lung disease | Cairo University | Completed | No outcome recorded |
| — | NCT03415828 Comparator | May 2018 → Feb 2024 overdue | lumbar disk disease | Gelscom SAS | Recruiting | No outcome recorded |
| — | NCT03705884 Background | Oct 2017 → Dec 2018 | cardiac sarcoidosis | University of Edinburgh | Completed | No outcome recorded |
| — | NCT03091010 Comparator | Apr 2017 → Mar 2019 | alcoholic hepatitis | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT02954939 Comparator | Mar 2017 → Dec 2028 expected | lupus nephritis | The University of Hong Kong | Recruiting | No outcome recorded |
| — | NCT04870359 Comparator | Apr 2016 → Mar 2022 | lupus nephritis | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT02416128 Comparator | Apr 2015 → Mar 2016 | iritis | Larkin Community Hospital | Withdrawn | No outcome recorded |
| — | NCT02162810 Comparator | May 2014 → May 2022 | hypospadias | Francis Schneck | Terminated | No outcome recorded |
| — | NCT02328079 Comparator | Apr 2013 → Nov 2014 | facial paralysis | Assiut University | Completed | No outcome recorded |
| — | NCT07074951 Background | Mar 2013 → Mar 2026 overdue | IgA glomerulonephritis | St. Petersburg State Pavlov Medical University | Recruiting | No outcome recorded |
| — | NCT01580865 Background | May 2012 → Mar 2017 | lupus nephritis | Ramathibodi Hospital | Completed | No outcome recorded |
| — | NCT02206789 Comparator | Feb 2012 → Feb 2017 | transplant rejection | Aravind Eye Care System | Unknown | No outcome recorded |
| — | NCT01843868 Background | Jan 2012 → Jun 2015 | non-Hodgkin lymphoma | Australasian Leukaemia and Lymphoma Group | Withdrawn | No outcome recorded |
| — | NCT01843920 Background | Jun 2011 → Apr 2013 | — | Jason Hsu, MD | Completed | No outcome recorded |
| — | NCT00931957 Background | Oct 2010 → Oct 2012 | Behcet disease, uveal disorder | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT01800708 Comparator | Jan 2010 → Mar 2013 | cataract | Fundação Altino Ventura | Completed | No outcome recorded |
| — | NCT00744224 Comparator | Feb 2009 → Jan 2010 | glucose metabolism disease | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT01245036 Comparator | Jan 2009 → Dec 2012 | sarcoidosis, tuberculosis | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| — | NCT01276314 Comparator | Jan 2009 → May 2015 | drug allergy | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT01014221 Comparator | Jul 2007 → Feb 2009 | carpal tunnel syndrome | Kuang Tien General Hospital | Completed | No outcome recorded |
| — | NCT00478036 Comparator | May 2007 → Jan 2014 | open-angle glaucoma | University of Colorado, Denver | Terminated | No outcome recorded |
| — | NCT00485108 Comparator | Jan 2007 → Jun 2009 | exfoliation syndrome, open-angle glaucoma | Queen's University | Completed | No outcome recorded |
| — | NCT00550992 Background | Jan 2006 → Dec 2020 | leukemia | Dutch Childhood Oncology Group | Unknown | No outcome recorded |
| — | NCT00343369 Background | Jan 2003 → ? | leukemia | University Medical Center Hamburg-Eppendorf | Unknown | No outcome recorded |
| — | NCT00555607 Comparator | Mar 2002 → Apr 2005 overdue | asthma, chronic obstructive pulmonary disease | Karolinska Institutet | Active not recruiting | No outcome recorded |
| — | NCT00141648 Background | Sep 2000 → Feb 2007 | primary bone lymphoma | Trans Tasman Radiation Oncology Group | Completed | No outcome recorded |
| — | NCT00004430 Background | Sep 1994 → Sep 1998 | corneal neovascularization | Medical College of Hampton Roads | Completed | No outcome recorded |
| — | NCT00798616 Comparator | — | bronchiolitis | University Hospitals Cleveland Medical Center | Withdrawn | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT01217697 Background | — | prostate cancer, urinary system neoplasm | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Approved for marketing | No outcome recorded |
| — | NCT01834209 Background | — | prostate neoplasm | Janssen Research & Development, LLC | No longer available | No outcome recorded |
| — | NCT05401214 Background | — | prostate carcinoma | Janssen Research & Development, LLC | Approved for marketing | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-06-19 | Roche Global Development | Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints roche.com ↗ |
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 789 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | prednisolone | “Weeks 1 - 4, Prednisolone 1mg/kg/day (max 80mg); Weeks 5 - 6: Prednisolone 0.8mg/kg/day (max 60mg); Weeks 7 - 8: Prednisolone 0.6mg/kg/day (max 50mg); Weeks 9 - 10:...” NCT07151456 ↗668“One hundred forty subjects received either a 0.59-mg FA intravitreal implant (n = 66) or standard of care (SOC; n = 74) with either systemic prednisolone or equivalent...” PMID 20079922 ↗ Jan 2010 “METHODS: Patients scheduled to undergo phacoemulsification and with no recognized CME risks (diabetic retinopathy, retinal vascular disease, or macular abnormality) were...” PMID 18599019 ↗ Jul 2008 “Patients initially received one 21-day cycle of standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP; rituximab 375 mg/m2, cyclophosphamide...” PMID 30948276 ↗ Apr 2019 “All enrolled patients will first complete a total of 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy (Rituximab + Cyclophosphamide + Doxorubicin + Prednisolone)...” NCT05874778 ↗ “Participants also received prednisolone 0.75 to 1.0 milligrams per kilogram (mg/kg), PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg...” NCT00425438 ↗ “Children received prednisolone at a dose of 60 mg/m2 per day for 4-8 weeks or less if they reached absence of proteinuria for 3 consecutive days, followed by 40 mg/m2 on...” NCT06860620 ↗ “This study evaluates the addition of Acalabrutinib to current standard therapy of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) for patients...” NCT04546620 ↗ “The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1),...” NCT01279902 ↗ “Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3...” NCT06732622 ↗ “Prednisolone as 5 mg tablets (Tianjin Lisheng Pharmaceutical Co., Ltd., China) were given as a single dose of 30 mg daily for the first 3 days; 15 mg daily for the following 3...” NCT06280794 ↗ “All patients will receive 8 cycles of R-CHOEP immunochemotherapy every two weeks with the following doses per cycle: rituximab 375 mg/m², cyclophosphamide 750 mg/m²,...” NCT03399513 ↗ “The prednisolone at a dose of 2 mg/kg per day (maximum 60 mg in single or divided doses) for 6 weeks, followed by 1.5 mg/kg (maximum 40 mg) as a single morning dose on...” NCT05850546 ↗ “Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally...” NCT03856229 ↗ “This study will compare an experimental drug called Z102 (combination of prednisolone and dipyridamole, against prednisone 5mg and prednisone 7.5mg in patients with moderate to...” NCT01612377 ↗ “Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg)...” NCT01245036 ↗ “Patients assigned to the corticosteroid group will receive (pulse) methylprednisolone succinate 500-1000 mg/day for 3 consecutive days followed by oral prednisolone (0.5...” NCT04662723 ↗ “3 daily pulses of 750 mg of intravenous Methylprednisolone, followed by oral corticosteroid therapy starting with a dose of 0.5 mg / kg / day for 4 weeks, then decreased by 2.5...” NCT05207358 ↗ “Oral prednisolone will be initiated at a dose of 0.5 to 1.0 mg/kg body weight, not exceeded 60 mg/day (week 1) with a rapid decrease by 5 mg each subsequent week until a...” NCT07074951 ↗ “Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less...” NCT04762810 ↗ “Group one (control group) received R-CHOP standard chemotherapy {Rituximab, Cyclophosphamide, Hydroxyldaunorubicin (Doxorubicin)®, Vincristine (oncovin)®, prednisolone in the...” PMID 33394214 ↗ Jan 2021 “Oral prednisone \[or oral prednisolone\] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to...” NCT02991144 ↗ “1. Oral prednisolone based on body weight to achieve a daily dose of 2mg/kg/day not to exceed 40 mg per day for 5 days or its equivalent (provided in the emergency department)” NCT03952286 ↗ “Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks.” NCT05734794 ↗ “Both groups received oral prednisolone, starting at 1 mg/kg per day and tapered down to 0 mg according to a standard reduction scheme defined in the study protocol.” PMID 26952547 ↗ Mar 2016 “At Baseline, all participants switched to corticosteroids (CS) provided by the sponsor with the oral prednisone or prednisolone dose at 20, 30, 40, 50, or 60 mg QD.” NCT03725202 ↗ “Immunosuppression therapy comprises oral prednisolone (0.5-0.8 mg/kg/day; exact dose decided by the investigator, maximum dose not exceeding 60 mg/day) for 8 weeks” NCT03418779 ↗ “Gemox: Gemcitabine and Oxaliplatin； IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone； DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin.” NCT04342936 ↗ “CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) is currently regarded as a standard chemotherapy regimen for patients with newly diagnosed NHL.” NCT00930605 ↗ “Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.” NCT04921033 ↗ “Cyclophosphamide, vincristine and doxorubicin as a drip into the bloodstream (intravenously) and prednisolone (steroid) as tablets taken with or after food.” NCT00004112 ↗ “Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone” NCT00452361 ↗ “Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.” NCT04762784 ↗ “Prednison (or appropriate dose of methylprednisolone) will be initiated POD 2 at a dose of 20mg/day and slowly tapered down to 5 mg at the POD 7” NCT04114188 ↗ “Patients will be allocated as single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks” NCT04162379 ↗ “The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.” NCT03532022 ↗ “Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL” NCT00991744 ↗ “Control group: Treatment with oral prednisolone (5 mg) for 14 days (high dosage 1 mg/kg/day for 7 days and gradually taper in the next week)” NCT06467526 ↗ “Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0).” NCT00149890 ↗ “Nivolumab 40 mg (Day 2), Rituximab 375 mg/m2 (Day 1) and Prednisolone 60 mg/m2 (Days 1-5) are administered at constant unchangeable doses.” NCT06871007 ↗ “Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M” NCT00354731 ↗ “The ARPI drugs used in this study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi).” NCT04597125 ↗ “The treatment will initiate with a dose of 0.5 mg/kg/day prednisolone for two weeks and the dose will halve in the next two weeks.” NCT05212740 ↗ “We randomly assigned 174 patients to receive prednisolone plus N-acetylcysteine (85 patients) or only prednisolone (89 patients).” PMID 22070475 ↗ Nov 2011 “Prednisolone 5 mg, patients to take 4 tablets per day for 14 days then take Montelukast 10 mg tablet per day for another 14 days.” NCT02479074 ↗ “Prednisolone and methylprednisolone are also well known and used drugs, whose side effects are often dose and duration dependent.” NCT02571517 ↗ “BACOPP-D regimen which includes cyclophosphamide, adriamycin, dacarbazine, procarbazine, prednisolone, bleomycin and vincristine” NCT00188149 ↗ “3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy” NCT03399747 ↗ “By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day” NCT00195273 ↗ “Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy” NCT00795756 ↗ “Administration in association with Methylprednisolone IV (or Prednisolone PO) starting at 2 mg/kg/day in two administrations.” NCT05762640 ↗ “Standard of care treatment will be with either prednisolone 40 mg/day for 28 days or pentoxifylline 400 mg TID for 28 days.” NCT02776059 ↗ “Oral glucocorticoids commenced with prednisolone 1 mg/kg/day and were reduced over different lengths of time to 5 mg/kg/day” PMID 36155131 ↗ Sep 2022 “Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks.” NCT03133299 ↗ “concurrent low-dose glucocorticoid (such as prednisone 5 mg tablet twice daily/prednisolone 0.5 mg tablet once daily).” NCT00474383 ↗ “R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.” NCT04661007 ↗ “Duration of initial prednisolone therapy for first episode of childhood nephrotic syndrome based on time to response.” PMID 36405821 ↗ Nov 2022 “Prednisolone 1%, a topical steroid, is considered standard of care following cataract surgery to reduce inflammation.” NCT01193504 ↗ “The COPD patients will not take prednisolone/placebo, but will either smoke 2 real or dummy cigarettes prior to scan.” NCT00159354 ↗ “Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis” NCT03091010 ↗ “Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.” NCT00377637 ↗ “Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID” NCT00294684 ↗ “prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).” NCT00600535 ↗ “The OC group was given oral prednisolone starting 3 days post-ESD, initially at 30 mg/day, tapered over 8 weeks.” PMID 41926323 ↗ Mar 2026 “Docetaxel can be administered in combination with prednisone/prednisolone at the discretion of the researcher.” NCT07503379 ↗ “prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses” NCT01541176 ↗ “twice-daily dosing of prednisolone (Pred Forte) is as effective as four-times-daily dosing of prednisolone” NCT00469781 ↗ “prednisolone (PRED) (0.8mg/kg/d) plus mycophenolate mofetil (MMF) (1g bd) as induction-maintenance therapy” NCT02954939 ↗ “Second generation ARPI (Abiraterone Acetate and Prednisolone, Enzalutamide, Apalutamide or Darolutamide).” NCT06320067 ↗ “Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks.” NCT02440009 ↗ “Prednisolone will be commenced with dose of 0.5mg/kg/day and will be tapered and off within 6 months.” NCT02198248 ↗ “prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily” NCT01664728 ↗ “CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles” NCT01649856 ↗ “The purpose of this study is to assess the pharmacodynamics of Prednisolone in healthy male subjects” NCT03196557 ↗ “Treatment-naive ABPA subjects randomly received either high-dose or medium-dose oral prednisolone.” PMID 26585431 ↗ Nov 2015 “Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks.” NCT01321827 ↗ “a total of 10mg of prednisolone per day when needed according to the decision of the researcher” NCT06306612 ↗ “VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone)” NCT01173887 ↗ “Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.” NCT03497273 ↗ “oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable” NCT02442180 ↗ “The initial dose of prednisone/prednisolone was 0.5-1 mg/kg/d (the maximum dose was 70 mg/d)” NCT05532111 ↗ “R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))” NCT02054559 ↗ “Patients will receive corticosteroids therapy: 1mg/kg of prednisolone daily for seven days.” NCT03553342 ↗ “Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet.” NCT01282073 ↗ “prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily)” NCT04381936 ↗ “Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.” NCT01326494 ↗ “followed by oral prednisolone 1 mg/kg daily but not exceeding 60 mg daily during week 1.” NCT05679336 ↗ “Standard of care post op drops-Prednisolone acetate and Ofloxacin, without pilocarpine” NCT04005079 ↗ “oral corticosteroid in the form of ,prednisolone60mg in two divided doses for 2 weeks.” NCT05112354 ↗ “Prednisone or prednisolone per standard of care to obtain control of disease activity.” NCT04206553 ↗ “combined with glucocorticoid therapy, oral prednisolone, initial dose of 0.5mg/(kg·d)” NCT05514015 ↗ “Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).” NCT00664599 ↗ “Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)” NCT03192969 ↗ “Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil” NCT06155604 ↗ “prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation” NCT03517085 ↗ “5. Prednisolone: 30mg orally three times daily on day 1-5 of every cycle.” NCT06918015 ↗ “according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent” NCT00862979 ↗ “prednisone or prednisolone, alone or in combination with hydrocortisone” NCT02716818 ↗ “TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group)” NCT01580865 ↗ “IT cytarabine, methotrexate, and either prednisolone or hydrocortisone” NCT03793478 ↗ “gemcitabine 800 mg/m2 and prednisolone 100 mg per day on days 1 and 4” NCT07450508 ↗ “oral therapy with Tab. Prednisolone 20mg BD will be given for 14days” NCT07454772 ↗ “glucocorticoid ( prednisone/prednisolone) 0.5mg/kg (maximum 40mg/d)” NCT06654596 ↗ “Rituximab, Cyclophosphamide, Adriamycin, Vincristine, Prednisolone” NCT02890602 ↗ “After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage” NCT02351427 ↗ “Glucocorticoids (prednisone or prednisolone) will be administered” NCT07569081 ↗ “Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF” NCT01046825 ↗ “Rituximab Doxorubicin Vincristine Cyclophosphamide Prednisolone” NCT01843868 ↗ “Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day” NCT02670707 ↗ “pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day.” NCT00849888 ↗ “received systemic steroids oral prednisolone tablet, 10 mg/day” NCT03852355 ↗ “Ster ® (prednisolone 1% ophthalmic suspension - União Química)” NCT01227876 ↗ “Tapering dose of dexamethasone or prednisolone upto 8 weeks” NCT05917340 ↗ “Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day” NCT03939637 ↗ “Prednisone/Prednisolone (at the investigator's discretion)” NCT07172685 ↗ “Prednisolone may be given if prednisone is unavailable.” NCT04023916 ↗ “a rescue pack (prednisolone and antibiotics for 5 days)” NCT06347536 ↗ “Prednisolone 40 mg once daily for 7 days as inpatients.” NCT07075315 ↗ “Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day” NCT01491815 ↗ “Solumedrol, dexamethasone,prednisolone, azithromycin” NCT04871633 ↗ “500 mg dose of Abiraterone Acetate plus prednisolone” NCT06193993 ↗ “Oral Prednisolone will be used in the Control Group” NCT03876444 ↗ “* Steroids: prednisolone 1.5 mg, prednisone 0.5 mg” NCT01734759 ↗ “oral prednisolone (0.5-1.0 mg/kg/day) for 27 days” NCT00354198 ↗ “adding small doses of prednisolone (10 mg) daily” NCT01724268 ↗ “prednisolone 30 mg orally (PO) every other day” NCT01302392 ↗ “Other Name: Enalapril, Lorsartan, Prednisolone” NCT02571842 ↗ “Docetaxel-prednisolone (TAX327 regimen) alone” NCT01487902 ↗ “Other Name: Prednisolone / Methylprednisolone” NCT07098897 ↗ “500 mg Prednisolone will be administered i.v.” NCT00604357 ↗ “prednisone, methylprednisolone, prednisolone” NCT06585774 ↗ “prednisone, prednisolone, methylprednisolone” NCT06388564 ↗ “T Prednisolone 40mg D1-D7 of a 21 day cycle” NCT01304849 ↗ “Capsule with tablet of Prednisolone 37,5mg” NCT01762540 ↗ “Prednisolone 5 mg twice a day orally daily” NCT01487720 ↗ “* Prednisolone p.o.: 40 mg/m² (D1 to D5)” NCT05820841 ↗ “Prednisolone 60 mg/m2/day tid days 1-28” NCT05827549 ↗ “lipid emulsion \& prednisolone \& LMWH” NCT03792997 ↗ “Basiliximab, Tacrolimus, Prednisolone” NCT07572071 ↗ “combined treatment with prednisolone” NCT00723086 ↗ “Prednisolone 100mg/m2, p.o., Day 1-5” NCT03151044 ↗ “Prednisolone 60 mg/m2/day po (d1-28)” NCT00844298 ↗ “25 mg prednisolone daily for 5 days” NCT04463420 ↗ “methylprednisolone and prednisolone” NCT00554502 ↗ “Corticosteroid ("prednisolone")” NCT03821155 ↗ “prednisolone 100 mg p.o. d 1-5” NCT00517894 ↗ “Prednisolone plus dipyridamole” NCT00747214 ↗ “Prednisolone 100mg PO d1-5” NCT05230680 ↗ “Prednisone® /Prednisolone®” NCT05468320 ↗ “prednisolone 500 mg” NCT04263584 ↗ “Drug: Prednisolone” NCT03206671 ↗ “Drug: Prednisolone” NCT06471465 ↗ “Predniso(lo)ne” NCT02191930 ↗ “Prednisolone” NCT07341776 ↗ “Prednisolone” NCT00355862 ↗ “prednisolone” NCT02981212 ↗ “prednisolone” NCT02872597 ↗ “Prednisolone” NCT05345171 ↗ “Prednisolone” NCT03571308 ↗ |
| Known as | Aprednislon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00888901 ↗ |
| Known as | Deltacortril | “Budesonide (Budenofalk®), Prednisolone (Deltacortril®), Azathioprine (Imuran®)” NCT04921033 ↗ |
| Known as | Glucocorticoids | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02523300 ↗ |
| Known as | Nanocort | “Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).” NCT01647685 ↗1“PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®)” NCT01601106 ↗ |
| Known as | NSC-9900 | “PRDL Prednisolone, NSC-9900” NCT00002576 ↗ |
| Known as | oral steroid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03490487 ↗ |
| Known as | PDN | “prednisolone (PDN) or PDN monotherapy” PMID 40781621 ↗ Aug 2025 |
| Known as | PRDL | “Patients receive oral prednisolone (PRDL) twice daily or methylprednisolone IV over 1 hour every 12 hours on days 1-7.” NCT00003728 ↗6“methotrexate (MTX) and prednisolone (PRDL) intrathecally (IT)” NCT00550992 ↗ “oral prednisolone (PRDL) 3 times a day on days 1-7” NCT00002531 ↗ “oral prednisolone (PRDL) on days 1-5” NCT00003815 ↗ “PRDL Prednisolone, NSC-9900” NCT00002576 ↗ “PRDL Prednisolone, NSC-9900” NCT00002757 ↗ “oral prednisolone (PRDL)” NCT00025064 ↗ |
| Known as | PRED | “prednisolone (PRED) (0.8mg/kg/d) plus mycophenolate mofetil (MMF) (1g bd) as induction-maintenance therapy” NCT02954939 ↗1“80 mg of oral prednisolone (PRED) every day (q.d.)” PMID 21216851 ↗ Jan 2011 |
| Known as | Pred Fort | “Pred Fort ® (prednisolone 1% ophthalmic suspension - Allergan)” NCT01227876 ↗ |
| Known as | Pred Forte | “prednisolone acetate ophthalmic suspension 1% (Pred Forte; Allergan, Inc., Irvine, CA) for endogenous anterior uveitis.” PMID 20809807 ↗ Oct 201012“Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of” NCT04426734 ↗ “twice-daily dosing of prednisolone (Pred Forte) is as effective as four-times-daily dosing of prednisolone” NCT00469781 ↗ “topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)” NCT02625467 ↗ “Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]” NCT04362241 ↗ “topical prednisolone acetate 1% (PredForte) eye drops” NCT06235567 ↗ “Prednisolone Acetate 1% (Pred Forte®)” NCT00833495 ↗ “1.0% prednisolone acetate, Pred Forte” NCT07136805 ↗ “Steriod eye drop: Pred Forte” NCT01673191 ↗ |
| Known as | pred forte (Prednisolone acetate1% ) | “pred forte (Prednisolone acetate1% )” NCT02206789 ↗ |
| Known as | Pred Mild | “Prednisolone Acetate 0.12% (Pred Mild®)” NCT00833495 ↗ |
| Known as | PredA | “Prednisolone acetate (PredA) 1% ophthalmic solution” NCT01769352 ↗ |
| Known as | Prednefrin | “Prednefrin® SF. Prednisolone Acetate 1%.” NCT03693989 ↗ |
| Known as | Prednefrin SF | “Prednefrin® SF. Prednisolone Acetate 1%.” NCT03693989 ↗ |
| Known as | Prednesol 5mg | “Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.” NCT03698630 ↗ |
| Known as | Prednisolon | “Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate,...” NCT00552526 ↗8“Prednisolone, first dose 2 mg/kg, then 2 mg/kg/d/3 (max. 60 mg/vrk) p.o. for 3 d (5 mg tabletti, Prednisolon ®, Leiras, Finland).” NCT00494624 ↗ “Cyclophosphamide 100 mg QD combine with prednisolon 1.0 mg/kg/day” NCT01288131 ↗ “Prednisolon will be given in case of worsening of symptoms” NCT03601611 ↗ |
| Known as | Prednisolone (as Acetate) | “Drug: Prednisolone (as Acetate)” NCT04705584 ↗ |
| Known as | Prednisolone acetate | “An option in this regard is a topical formulation of prednisolone acetate, moxifloxacin hydrochloride and ketorolac tromethamine (PredMoxiKetorolac), given for one week...” NCT02819908 ↗92“The objective of this study is to compare the efficacy and safety of topical Loteprednol Etabonate (LE), 0.5%, to Prednisolone Acetate 1%, for the treatment of postoperative...” NCT01475643 ↗ “To compare the efficacy of twice-daily topical bromfenac (Xibrom) ophthalmic solution alone versus twice-daily topical Xibrom with prednisolone acetate 1% three-times daily on...” NCT00698724 ↗ “Topical Prednisolone acetate 1.0% Topical eye drops 4 times per day for 2 weeks followed by 4 times daily for 2 weeks, then twice daily for 2 weeks and finally once daily for 2 weeks.” NCT04705584 ↗ “All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .” NCT04451239 ↗ “Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%.” NCT03626376 ↗ “standard topical drops regimen that includes the topical use of Gatifloxacin, Bromfenac and Prednisolone acetate 1%.” NCT03578276 ↗ “Patients were randomized 2:1 to topical TRS01 1% or prednisolone acetate 1% administered 4 times daily for 28 days.” PMID 41485727 ↗ Jan 2026 “Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop” NCT05157113 ↗ “Triple-drugs therapy: "Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops" for 3 weeks.” NCT06474416 ↗ “Triple-drugs therapy: "Ganciclovir Eye gel+Valacilovir Tablets+Prednisolone Acetate Eye Drops" for 3 weeks.” NCT06474442 ↗ “Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day” NCT03383328 ↗ “The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim” NCT01843920 ↗ “Postoperative treatment started with prednisolone acetate 1% eye drops five times daily” NCT00450996 ↗ “Prednefrin® SF. Prednisolone Acetate 1%. Prepared by Allergan, S.A. of C.V.” NCT03693989 ↗ “topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)” NCT02625467 ↗ “prednisolone acetate 1% QID 1 week, TID 1 week, BID 1 week, and QD 1week” NCT04549935 ↗ “sulfacetamide sodium 10%/prednisolone acetate 0.2%, Allergan, Inc.” NCT02256969 ↗ “Suspension of Prednisolone Acetate administered during 28 days” NCT01120132 ↗ “Received prednisolone acetate 1% eye drops six times daily.” NCT07496060 ↗ “Prednisolone acetate (PredA) 1% ophthalmic solution” NCT01769352 ↗ “Tobramycin prednisolone acetate combination” NCT00854061 ↗ “Tobramycin prednisolone acetate combination” NCT00699803 ↗ |
| Known as | Prednisolone Acetate Ophthalmic Suspension | “Prednisolone Acetate Ophthalmic Suspension” NCT06474416 ↗ |
| Known as | Prednisolone Fort | “2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran” NCT02439866 ↗ |
| Known as | Prednisolone metasulfobenzoate sodium | “The active ingredient in each tablet consists of Prednisolone metasulfobenzoate sodium 31.44 mg (equivalent to 20 mg of Prednisolone).” NCT04652739 ↗ |
| Known as | prednisolone phosphate | “prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week” NCT00324168 ↗ |
| Known as | Prednisolone Sodium Phosphate | “Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%.” NCT03626376 ↗6“PEG-liposomal Prednisolone Sodium Phosphate (Nanocort) in Atherosclerotic Tissue” NCT01647685 ↗ |
| Known as | Prezolon | “5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test” NCT01590173 ↗ |
| Known as | PSL | “prednisolone (PSL)” NCT00627731 ↗ |
| Known as | Ster | “Ster ® (prednisolone 1% ophthalmic suspension - União Química)” NCT01227876 ↗ |
| Known as | steroid therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07235488 ↗ |
| Known as | Tab. Prednisolone | “oral therapy with Tab. Prednisolone 20mg BD” NCT07454772 ↗ |
| Action | Inhibit | “Steroids inhibit the effect of gluten proteins through their action on elements of the immune system.” NCT01045837 ↗ |
| Modality | Other / unclassified | “a type of steroid medication” NCT00057421 ↗ |
| Route | Topical | “topical prednisolone phosphate drops” NCT00000138 ↗ |